Moreover, studies have reported that P2X7 receptor antagonist decreased astrogliosis, abridged demyelination, and improved neurological symptoms in an EAE rat model of MS (Grygorowicz et al., 2016). Here, P2RX7 is linked to myeloid sarcoma.